Current directions in tau research: Highlights from Tau 2020
Sexton C, Snyder H, Beher D, Boxer A, Brannelly P, Brion JP, Buée L, Cacace A, Chételat G, Citron M, DeVos S, Diaz K, Feldman H, Frost B, Goate A, Gold M, Hyman B, Johnson K, Karch C, Kerwin D, Koroshetz W, Litvan I, Morris H, Mummery C, Mutamba J, Patterson M, Quiroz Y, Rabinovici G, Rommel A, Shulman M, Toledo-Sherman L, Weninger S, Wildsmith K, Worley S, Carrillo M.
> Read more
Alzheimer's disease mutations in APP but not gamma-secretase modulators affect epsilon-cleavage-dependent AICD production.
> Read more
Generation and characterization of a rabbit monoclonal antibody site-specific for tau O-GlcNAcylated at serine 400.
> Read more
Substrate determinants in the C99 juxtamembrane domains differentially affect γ-secretase cleavage specificity and modulator pharmacology.
Ousson S, Saric A, Baguet A, Losberger C, Genoud S, Vilbois F, Permanne B, Hussain I, Beher D.
J Neurochem. 125 (2013), 610-619
> Read more
The role of γ-Secretase Activating Protein, GSAP and imatinib in the regulation of γ-secretase activity and amyloid-β generation.
Hussain I, Fabregue J, Anderes L, Ousson S, Borlat F, Eligert V, Berger S, Dimitrov M, Alattia JR, Fraering PC, Beher D.
J Biol Chem. 2013 Jan ; 288 (4): 2521-31
> Read more
Development and Characterization of a Novel Membrane Assay for Full-Length BACE-1 at pH 6.0.
Saric A, Brügge LZ, Müller-Pompalla D, Rysiok T, Ousson S, Permanne B, Quattropani A, Busch M, Beher D, Hussain I.
J Biomol Screen. 2012 Sep 27. [Epub ahead of print]
> Read more
Discovery of γ-secretase modulators with a novel activity profile by text-based virtual screening.
Zettl H, Ness J, Hähnke V, Beher D, Jumpertz T, Saric A, Baumann K, Pietrzik CU, Bulic B, Schneider G, Weggen S.
ACS Chem Biol. 2012 Sep 21;7(9): 1488-95.
> Read more
Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease.
Weggen S, Beher D.
Alzheimers Res Ther. 2012 Mar 30;4(2):9
> Read more
